Stieltjes Natalie, Torchet Marie F, Misrahi Laure, Roussel-Robert Valérie, Lambert Thierry, Guérois Claude, Bertrand Marie A, Briquel Marie E, Borel-Derlon Annie, Dirat Gérard
Centre des hémophiles, Hôpital Cochin, Paris, France.
Blood Coagul Fibrinolysis. 2009 Jan;20(1):4-11. doi: 10.1097/mbc.0b013e328313fc8e.
The physical condition of severe haemophilia and the impact of advances in replacement therapy have been much studied, but little work has been done on patients who developed inhibitors. The 'Statut Orthopédique des Patients Hémophiles avec Inhibiteur' study was conducted in France in order to assess the orthopaedic status and quality of life of such patients, and the cost of their medical management. Fifty haemophiliacs aged 12-63 years with a history of high-responder inhibitors were included. Clinical assessment showed that only 12% of the patients had a nil pain score and 2% a nil clinical score, as per Gilbert scale. The mean clinical score was significantly higher in patients over 35 years of age than in younger ones. However, younger patients appeared to have a more impaired orthopaedic status than young haemophiliacs without inhibitors of similar age in previous published cohorts. Surprisingly, older haemophiliacs tended to have the best mental quality of life, contrasting with their highly impaired orthopaedic condition and physical quality of life. The mean cost of clinical resources consumed during the year preceding enrolment was Euro 268 999, 99% of which was related to clotting factor. Marked between-patient differences in cost were noted. Our study suggests that the management of haemophiliacs with inhibitors should be improved in order to prevent haemophilic arthropathy to an extent similar to that of patients without inhibitors. Cost-benefit assessment of any therapeutic strategy should always be combined with quality-of-life evaluation.
重度血友病的身体状况以及替代疗法进展的影响已得到大量研究,但针对产生抑制剂的患者所做的工作却很少。“伴有抑制剂的血友病患者的骨科状况”研究在法国开展,旨在评估此类患者的骨科状况、生活质量及其医疗管理成本。纳入了50名年龄在12至63岁之间、有高反应性抑制剂病史的血友病患者。临床评估显示,按照吉尔伯特量表,只有12%的患者疼痛评分为零,2%的患者临床评分为零。35岁以上患者的平均临床评分显著高于年轻患者。然而,与先前发表队列中年龄相仿的无抑制剂血友病年轻患者相比,年轻患者的骨科状况似乎受损更严重。令人惊讶的是,年龄较大的血友病患者往往具有最佳的心理生活质量,这与其严重受损的骨科状况和身体生活质量形成反差。入组前一年消耗的临床资源平均成本为268999欧元,其中99%与凝血因子有关。注意到患者之间在成本上存在显著差异。我们的研究表明,应改进对伴有抑制剂的血友病患者的管理,以在与无抑制剂患者相似的程度上预防血友病性关节病。任何治疗策略的成本效益评估都应始终与生活质量评估相结合。